National Peroxide Ltd.

As of March 31, 2026, National Peroxide Ltd. carries a market capitalization of 2.02B, placing it among publicly traded companies globally. Its enterprise value stands at 1.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, National Peroxide Ltd. has 5.75M shares outstanding.

As of March 31, 2026, National Peroxide Ltd. trades at a trailing price-to-earnings ratio of 18.27. The price-to-sales ratio is 0.70, and the price-to-book ratio stands at 0.57.

As of March 31, 2026, National Peroxide Ltd. trades at an EV/EBITDA multiple of 4.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.73 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.45B versus a market cap of 2.02B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, National Peroxide Ltd. maintains a current ratio of 2.77, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.56, indicating elevated leverage, while an interest coverage ratio of 22.58 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, National Peroxide Ltd. posted a return on equity (ROE) of 3.13, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.04 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.45, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.29, useful for judging operating efficiency across full business cycles. The company generates approximately 23.36M in revenue per employee across its workforce of 124.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.77 indicates how many times National Peroxide Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, National Peroxide Ltd. recorded 33.95M in income tax expense. That works out to an effective tax rate of 23.52, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 144.32M, leaving 110.37M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, National Peroxide Ltd.'s stock has declined approximately 13.61% over the past 52 weeks. The 50-day moving average sits at 608.72, while the 200-day moving average is 521.72.

Over the twelve months ended March 31, 2026, National Peroxide Ltd. generated 2.90B in revenue and converted that into 110.37M in net income, yielding earnings per share of 19.20. EBITDA reached 305.97M, while operating income came in at 103.89M.

As of March 31, 2026, National Peroxide Ltd. holds 698.45M in cash and equivalents against 127.14M in total debt, resulting in a net debt position of -152.84M. Total book value stands at 3.57B, with working capital of 887.46M providing operational flexibility.

Over the twelve months ended March 31, 2026, National Peroxide Ltd. posted a gross margin of 54.12, reflecting its pricing power and cost economics. The operating margin of 3.59 and net profit margin of 3.81 provide insight into operational efficiency.

As of March 31, 2026, National Peroxide Ltd. has an Altman Z-Score of 2.26, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.